Gazyva (obinutuzumab) / Roche, Biogen |
NCT01414205: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) |
|
|
| Completed | 2 | 80 | US | Obinutuzumab, RO5072759; GA101, Corticosteroids | Genentech, Inc. | Lymphocytic Leukemia, Chronic | 03/13 | 03/16 | | |
|
|
NCT01868893: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 20 | US | Obinutuzumab, RO 5072759, GA101, Chlorambucil | Genentech, Inc. | Chronic Lymphocytic Leukemia | 01/14 | 01/14 | | |
|
| Completed | 2 | 66 | Europe | Bendamustine, GA101, Obinutuzumab, Ibrutinib | German CLL Study Group, Hoffmann-La Roche, Janssen-Cilag Ltd. | Chronic Lymphocytic Leucemia | 08/16 | 03/19 | | |
NCT02320383 / 2013-001088-22: CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients |
|
|
| Unknown status | 2 | 27 | Europe | GA101 (Obinutuzumab), Gazyvaro, Bendamustine, Ribomustin, Levact | Munich Municipal Hospital, German CLL Study Group | Chronic Lymphocytic Leucemia | 12/17 | 09/22 | | |